Deferred Royalty Obligation related to the Sale of Future Royalties - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2025	Dec. 31, 2024
Deferred Royalty Obligation [Line Items]
Non-cash interest expense on deferred royalty obligation		$ 38,208	$ 31,070
Percentage of interest rate amortize liability		17.80%
Blackstone Life Sciences
Deferred Royalty Obligation [Line Items]
Upfront payment received	$ 140,000
Blackstone Life Sciences \| Maximum
Deferred Royalty Obligation [Line Items]
Milestone payment receivable	250,000
2015 License Agreement \| Blackstone Life Sciences
Deferred Royalty Obligation [Line Items]
Transaction costs incurred	3,800
2015 License Agreement \| Blackstone Life Sciences \| Royalty
Deferred Royalty Obligation [Line Items]
Upfront payment received	$ 140,000
Revenue interest percentage	4.00%	4.00%
Amendment 3 2015 License Agreement \| Vaxcyte \| Royalty
Deferred Royalty Obligation [Line Items]
Revenue interest percentage		4.00%